Skip to main content

Table 1 Associations between patient clinicopathologic factors and response to gefitinib

From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Variable

Total (n = 66) (%)

Response to gefitinib treatment

PR (N = 25)

SD (n = 20)

PD (n = 21)

P value (PR vs SD + DP)

P value (PR + SD vs PD)

Sex

      

 Male

37(56.1)

11

9

17

0.136

0.007

 Female

29(43.9)

14

11

4

  

Age, yr

      

 <67

34(51.5)

11

11

12

0.447

0.603

 ≥67

32(48.5)

14

9

9

  

Smoking history

      

 Never

22(33.3)

11

7

4

0.187

0.112

 Former

18(27.3)

6

5

7

  

 Current

26(39.4)

8

8

10

  

Histology

      

 ADC

39(59.1)

20

12

7

0.022

0.004

 SCC

22(33.3)

4

6

12

  

 ASC

5(7.6)

1

2

2

  

Performance status

      

 0-1

52(78.8)

19

16

17

0.760

0.421

 2-3

14(21.2)

6

4

6

  

Disease stage

      

 IIIB

10(15.2)

5

2

3

0.729

0.945

 IV

56(84.8)

22

16

18

  

Prior chemotherapy

      

 Yes

46(69.7)

18

16

12

0.790

0.157

 No

20(30.3)

7

4

9

  

EGFR status

      

 Wild-type

38(57.6)

9

11

18

0.018

0.005

 Mutation

22(33.3)

12

8

2

  

 Unknown

6(9.1)

4

1

1

  

MUC1 mRNA at B0

      

 Median

5.95

4.87

5.18

8.76

0.116

0.005

 Range

1.16-17.56

1.16-8.75

2.45-10.73

2.24-17.56

  

VEGF mRNA at B0

      

 Median

4.88

4.21

4.72

7.65

0.122

0.004

 Range

1.07-15.32

1.07-9.86

1.62-10.24

2.31-15.32

  
  1. PR, partial response; SD, stable disease; PD, progressive disease; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ASC, adenosquamous cell carcinoma.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us